Prof. Mehmet Haberal is presented with The Award of The Spanish Order of The Civil Merit (Cruz de Official) by His Majesty King Felipe VI, King of Spain.
We are honored to announce that Prof. Dr. Seza Özen who is the member of Honorary Advisory Board of JBACHS has already won the Aziz Sancar Science Award of TUSEB.
We are happy to announce that The Journal of Basic and Clinical Health Sciences (JBACHS) is indexed by the Emerging Sources Citation Index since November 2017, and indexed by the Ulakbim-TR since 2017.
Journal of Basic and Clinical Health Sciences 2020 , Vol 4 , Issue 3
Are Angiotensin II Receptor Blockers for Hypertension a Gleam of Hope or not Against COVID-19 Infection?
Duygu Aydemir1,Nuriye Nuray Ulusu1
1Koc University, School of Medicine, Department of Medical Biochemistry, Istanbul, Turkey
2Koc University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey
DOI : 10.30621/jbachs.2020.1153 Numbers of infected people and deaths by COVID-19 are increasing every day worldwide and life has stopped to fight against this virus. There is an urgent need of a treatment against this pandemic. People having hypertension, cardiovascular diseases and diabetes conditions were reported as more vulnerable against COVID-19 infection. ACE2 is the entry receptor for COVID-19 virus and ACE2 blockers are widely used against abovementioned chronic diseases. ACE2 inhibitors can reduce oxidative stress levels in the tissues, when viral infections imbalance redox balance of the organs by elevating oxidative stress levels. Therefore, using ACE2 blockers may help to treat infected patients showing severe symptoms, especially the ones having diabetes, hypertension or cardiovascular diseases. However clinical trials are needed to understand whether this theory are correct or not. Keywords : COVID-19; angiotensin II receptor blocker; hypertension; cardiovascular disease; diab